



ORPHAN MEDICINAL PRODUCTS IN SPAIN

Market access situation for Orphan Medicinal Products (OMPs) with trade name, and with orphan designation in force as of 31 December 2024









AVERAGE WAITING TIME


MONTHS BETWEEN NC AND INCORPORATION INTO THE NHS









NUMBER OF OMPS NOT REIMBURSED BY YEAR OF NC




NUMBER OF OMPS NOT REIMBURSED BY THERAPEUTIC AREA





ADVANCED THERAPY MEDICINAL PRODUCTS (ATMPS)

WITH ORPHAN DESIGNATION







Note 1: Due to the fact that the information is not publicly available, this Report does not include those medicines used under the 'special situations' set out in Royal Decree 1015/2009, about compassionate use, use in conditions other than those authorised, or access to foreign medicines (available here: https://www.boe.es/eli/es/rd/2009/06/19/1015).

Note 2: Data in the figue referring to advance therapies with marketing authorisation, national code and reimbursed by NHS, are not cumulative.

*Cumulative data upto December 31, 2024.

**The 15 Advanced Therapies with OD and MA (Marketing Authorisation) are included in the total of 210 OMPs with OD, and in the 147 OMPs with MA, since they are Advanced Therapies with a commercial name.

Glossary: ATMPS (Advanced Therapy Medicinal Products) MA (Marketing Authorisation) NC (National Code)

NHS (National Health System)



